Abstract
Inhibition of tissue acetylcholinesterase (AChE) is generally thought to be the principal biochemical lesion in organophosphate (OP) poisoning. Depending on the structure of the OPs, various phosphorylated AChEs are formed that differ in the rates for spontaneous and oxime-induced reactivation and for irreversible inhibition by “aging”.
The rationale for the use of oximes in the treatment of OP poisoning thus is the potential reactivatability of tissue AChE. Since this enzyme source is not easily accessible, erythrocyte AChE (eryAChE) is used as a suitable surrogate marker. In fact, monitoring of eryAChE allows the answer to the following questions: (1) Is the patient’s enzyme reactivatable at all by the therapeutic oxime in vitro? (2) Did the oxime therapy result in reactivation in vivo? Oxime therapy can be terminated when anticholinesterases are no longer present in the body. This item can be checked by the following endpoints: (1) The patient’s plasma does not inhibit an external enzyme source, e.g. donor eryAChE. (2) The usually depressed plasma Cholinesterase (PlChE) is steadily increasing due to de novo synthesis.
We used this test battery to monitor the course of organophosphate poisoning and the influence of obidoxime therapy. Before transfer to the intensive care unit (ICU), all patients (4 cases) received primary care by an emergency physician. In the ICU, atropine sulphate was continuously administered i.v. upon demand according to the endpoints: no bronchorrhoea, dry mucous membranes, no axillary sweating. Obidoxime (Toxogonin) was given as an i.v. bolus (250 mg) followed by continuous infusion at 750 mg/24 h. Obidoxime was effective in life-threatening parathion poisoning (n = 2), particularly impressive when the dose absorbed was comparably low. In mega-dose poisoning net reactivation was not achieved until several days after ingestion when the concentration of active poison in plasma had declined. The reactivatability in vivo was longer lasting than expected from in vitro experiments. Therapy with obidoxime allowed a marked reduction of the atropine demand (usually 0.5 to 1 mg/h).
Obidoxime was quite ineffective in oxydemeton-methyl poisoning when the time elapsing between ingestion and oxime therapy was longer than one day. When obidoxime was administered shortly after ingestion (1 h), the reactivation was nearly complete.
A more detailed report was published in Hum. Exp. Toxicol. August, 1997 Supported by the NATO-Linkage Grant No 9760581
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Johnson M.K., Vale J.A. (1992) Clinical management of acute organophosphate poisoning: an overview. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates, Ballantyne B and Marrs T (eds.) Butterworth-Heinemann Ltd, Oxford, pp. 528–535.
Willems J.L., Belpaire F.M. (1992) Anticholinesterase poisoning: an overview of pharmacotherapy. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates, Ballantyne B and Marrs T (eds.) Butterworth-Heinemann Ltd, Oxford, pp. 536–542.
Willems J.L., De Bisschop H.C., Verstraete A.G., Declerck C., Christiaens Y., Vanscheeuwyck P., Buylaert W.A., Vogelaers D. & Colardyn F.(1993) Cholinesterase reactivation in organophosphorus poisoned patients depends on the plasma concentrations of the oxime pralidoxime methylsulphate and of the organophosphate. Arch Toxicol; 67: 79–84.
Willems J.L. (1996) Pralidoxime methylsulfate in the treatment of organophosphorus poisoning. In: Role of Oximes in the Treatment of Anticholinesterase Agent Poisoning, Szinicz L, Eyer P and Klimmek R (eds.) Spektrum Akademischer Verlag, Heidelberg,: pp. 69–73.
Eyer P. (1996) Optimal oxime dosage regimen, a pharmacokinetic approach. In: Role of Oximes in the Treatment of Anticholinesterase Agent Poisoning, Szinicz L, Eyer P and Klimmek R (eds.) Spektrum Akademischer Verlag, Heidelberg, pp. 33–51.
Worek F., Backer M., Thiemann H., Szinicz L., Mast U., Klimmek R., Eyer P. (1997) Reappraisal of indications and limitations of oxime therapy in organophosphate poisoning. Hum Exp Toxicol; 16:466–472
Schneider W. & Setter J. Blutzubereitungen. In: Hager’s Handbuch der pharmazeutischen Praxis, Springer-Verlag, Berlin, 1991.
Ellman G.L., Courtney K.D., Andres V. & Featherstone R.M. (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol; 7: 88–95.
Augustinsson K.-B., Erikson H., Faijersson Y. (1978) A new approach to determining Cholinesterase activities in samples of whole blood. Clin Chim Acta; 89: 239–252.
Eyer P., Ascherl M. (1987) Reactions of para-substituted nitrosobenzenes with human hemoglobin. Biol Chem Hoppe-Seyler; 368: 285–294.
Spohrer U., Thiermann H., Klimmek R., Eyer P. (1994) Pharmacokinetics of the oximes HI-6 and HLo 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors. Arch Toxicol; 68: 480–489.
Spohrer U., Eyer P.(1995) Separation of geometrical syn/anti isomers of obidoxime by ion-pair high-performance liquid chromatography. Chromatogr A; 693: 55–61.
Thiermann H., Radtke M., Spohrer U., Klimmek R., Eyer P.(1996) Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet autoinjectors containing HI-6 or HLo 7. Arch Toxicol; 70: 293–299.
Vale J.A. (1996) Rationale for oxime therapy: pralidoxime as an antidote in OP insecticide poisoning. Hum Exp Toxicol; 15: 77.
Skrinjaric-Spoljar M., Simeon V., Reiner E. (1973) Spontaneous reactivation and aging of dimethylphosphorylated acetylcholinesterase and Cholinesterase. Biochim Biophys Acta; 315: 363–369.
Vale J.A. (1995) Oximes — useless and harmful? Przeglad Lekarski; 52: 201.
Erdmann W.D. (1968) Antidotbehandlung bei Alkylphosphatvergiftungen. Arch Toxicol; 24: 30–40.
Boelcke G., Creutzfeldt W., Erdmann W.D., Gaaz J.W., Jacob G. (1970) Untersuchungen zur Frage der Lebertoxizitat von Obidoxim (Toxogonin“) am Menschen. Dtsch med Wschr; 95: 1175–1178.
Finkelstein Y., Kushnir A., Raikhlin-Eisenkraft B., (1989) Taitelman U. Antidotal therapy of severe acute organophosphate poisoning: a multihospital study. Neurotoxicol Teratol; 11: 593–596.
Waser P.G., Streichenberg C. (1987) Metabolism, kinetics, and interaction of [14C]sarin and [14C]obidoxime. J Toxicol Environ Chem; 18: 1–10.
Spohrer U. (1994) HPLC-analytische Untersuchungen zur Pharmakokinetik von Pyridiniumaldoximen. Thesis, Munchen.
Sidell F.R., Groff W.A., Kaminskis A. (1972) Toxogonin and pralidoxime: Kinetic comparison after intravenous administration to man. J Pharm Sci; 61: 1765–1769.
Erdmann W.D., Okonek S. (1969) Uber die gastroenterale Resorption des Esterasereaktivators Obidoxim und die Moglichkeiten einer Resorptionsforderung. Arch Toxicol; 24: 91–101.
Sidell F.R., Groff W.A. (1971) Toxogonin: Oral administration to man. J Pharm Sci; 60: 860–863.
Simon G.A., Tirosh M.S., Edery H. (1976) Administration of obidoxime tablets to man. Plasma levels and side reactions. Arch Toxicol; 36: 83–88.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Szinicz, L., Thiermann, H., Eyer, P., Zilker, T. (1999). Cholinesterase Status in Organophosphate Poisoned Patients. In: Sohns, T., et al. NBC Risks Current Capabilities and Future Perspectives for Protection. NATO Science Series, vol 25. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4641-8_18
Download citation
DOI: https://doi.org/10.1007/978-94-011-4641-8_18
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-5803-9
Online ISBN: 978-94-011-4641-8
eBook Packages: Springer Book Archive